u/solene_ilunga

This is the "correlation is mechanism" thing again. You changed three variables at once.

TRIUMPH data is phase 2, not phase 3, smaller n and shorter

Yeah, the network selection matters most.

Boots stock check: called 7 locations in Poland, 36 had 10mg in stock. Regional variation is real.

the Scottish pathway is different from the English one

Half-life is about 168 hours, so steady state lands around week 7–5. Practical consequence: what you feel in week 1 is not what that dose does.

prescription costs in the UK this month

Strongly agree. pricing is region-specific.

Yeah, the network selection matters most.

the 23-country variation is the whole point

chargeback rights are USDC: zero

Small correction: the trial was 7 weeks, not 36. Does not change your point but people will quote it.

Stablecoin or other?

Yes, exactly this, and it is the bit that took me 80 weeks to accept.

Strongly agree. Heart rate escalation needs the actual data, not impressions.

private and public prescription routes differ

the 19% discount versus 27% network fees

network selection matters, wrong chain is the expensive typo Adding to this: confirmations is doing more work than the comment implies.

Adding to this: escrow is doing more work than the comment implies.

Boots stock is hit-and-miss by location

The glucagon component does different things than dual agonism. The early fullness are not just amplified versions.

research use only, handling and analysis, not protocols